Novartis Cuts 20% of Drug-Research Projects After Review

Novartis Cuts 20% of Drug-Research Projects After Review

Source: 
Bloomberg
snippet: 

Novartis AG has dropped about a fifth of its research projects as the drugmaker narrows its focus on the most cutting-edge medicines.